Biophage Pharma Appoints Infectious Disease Expert To Scientific Advisory Committee
05-22-2007
Montreal, May 22, 2007 – (TSX.V: BUG). Biophage Pharma Inc. (Biophage) is pleased to announce the appointment of Dr. Maximilien Arella to its Scientific Advisory Committee. As a member of various national and international committees on infectious diseases and expression of recombinant proteins, Dr. Arella brings to Biophage his extensive research and international skills in the field of infectious diseases, molecular biology and monoclonal antibody development.
Dr. Arella received his Ph.D. in Virology from Institut Armand-Frappier/University of Quebec in 1983 and completed his post-doctoral training at Hoffmann-Laroche (New Jersey, USA). Since 1984 he has been a Professor of Virology at Institut Armand Frappier/University of Quebec, and was also director of the Virology Research Center between 1993 and 1998. He is an adjunct professor at both the University of Montreal and the University of Charlottetown.
Dr. Arella is currently on a leave-of-absence from the University and is presently engaged in several national and international projects. He is also involved as an investor and president of several national and international companies in the field of biotechnology, primarily relating to successful technology transfer projects in Japan and Europe. Dr. Arella sits on the board of several private and public companies, including international pharmaceutical companies.
“I am very pleased that Dr. Arella has decided to join our Scientific Advisory Committee. His experience and expertise in the field of immunology and infectious diseases as well as his national and international network of collaborators will be an important asset to Biophage. His contributions will enhance our ability to commercialize our products and services and expedite market penetration”, said Dr. Rosemonde Mandeville, President and Chief Executive Officer of Biophage Pharma.
“It will be a pleasure to bring my biomedical expertise to the Biophage Scientific Advisory Committee. Biophage’s current development programs are uniquely suited to take advantage of my own particular skill set. I look forward to incorporating my wide ranging scientific and entrepreneurial experiences, as well as my network of collaborators, to advance the development of Biophage pipeline of products and services, as well as technology transfer of projects related to the business at Biophage”, stated Dr. Arella.
AI
